For decades, one of the greatest challenges in dentistry has not been treating disease—it has been helping patients overcome their fear of treatment. Among the most common causes of dental anxiety is the fear of injections, a concern that affects millions of patients worldwide and often leads to delayed or avoided dental care.
Now, a new partnership between global dental leader Septodont and Australian medical technology company Dentroid is aiming to change that narrative.
The two companies have announced a strategic collaboration focused on advancing non-invasive dental pain management technologies, with the goal of making dental procedures more comfortable and less intimidating for patients.
A Partnership Built Around Innovation
Septodont is widely recognized for its long-standing expertise in dental anesthesia and pain management products. With decades of experience supporting dentists worldwide, the company has played a major role in shaping modern pain-control techniques in dentistry.
Dentroid, on the other hand, brings a fresh perspective to the field through its innovative Nuralyte® technology, a light-based system designed to manage dental pain without relying solely on traditional injections.
By combining Septodont’s global reach and clinical expertise with Dentroid’s cutting-edge technology platform, the partnership represents a significant step toward developing the next generation of patient-centered dental care.
How the Technology Works
At the heart of the collaboration is Nuralyte®, a technology based on photobiomodulation (PBM). Unlike conventional anesthesia, which relies on injectable medications to block nerve transmission, photobiomodulation uses carefully controlled light energy to interact with nerves and surrounding tissues.
The technology is being developed to help reduce discomfort during dental procedures and potentially decrease the need for local anesthetic injections in selected treatments.
While research and development are still ongoing, the concept offers an exciting glimpse into a future where managing dental pain may become less invasive and more comfortable for patients.
Looking Ahead
Although Nuralyte technology is still progressing through development and commercialization stages, the partnership signals growing interest in alternatives to traditional pain-management methods.
As research continues, dentists and patients alike will be watching closely to see whether light-based pain control can become a practical addition to everyday dental care.
If successful, this collaboration could mark the beginning of a new chapter in
The future of dental pain management may not eliminate injections entirely, but it could provide dentists with new tools to make treatment more accessible, less stressful, and more patient-friendly than ever before.
Referance
